DNAprint Genomics (DNAG)

[Theo]

NEWS: http://biz.yahoo.com/iw/051118/0101735.html

Press Release Source: DNAPrint genomics, Inc.

DNAPrint genomics to Present at Investor Conference Sponsored by the Wall Street Analyst Forum
Friday November 18, 7:00 am ET

SARASOTA, FL--(MARKET WIRE)--Nov 18, 2005 -- DNAPrint(TM) genomics, Inc. (OTC BB:DNAG.OB - News), a developer of genomics-based products and services, today announced that Dr. Barbara Handelin, the Company's General Manager of Computational Biology, will be presenting before The Wall Street Analyst Forum Institutional Investor Conference at The Roosevelt Hotel, Madison Avenue at 45th Street, in New York City at 11:00 a.m. Eastern time on Wednesday, November 30.

During the 40-minute presentation, which can also be heard via a live webcast on the Company's website at www.dnaprint.com or at http://www.investorcalendar.com/CEPage.asp?ID=97888, Dr. Handelin will provide an overview of the Company and discuss its goals and outlook for the future. The webcast will also be archived. To register for the conference, please visit www.analyst-conference.com or contact The Wall Street Group, Inc. at 212-888-4848.

The Wall Street Analyst Forum brings together financial analysts and portfolio managers who are interested in learning about the companies participating in the investor conference and provides them the opportunity to personally meet company personnel and learn more about the company.

About DNAPrint

DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).

ADVERTISEMENT
Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


Contact:

Company Contact:

Richard Gabriel
President and CEO
941-366-3400
-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848


Source: DNAPrint genomics, Inc.